ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement.
Imig
John D
JD
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001685:Biological Factors / Q000502:physiology*; D001920:Bradykinin / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D018450:Disease Progression; D004285:Dogs; D004359:Drug Therapy, Combination; D006801:Humans; D007668:Kidney / Q000098:blood supply*; D009569:Nitric Oxide / Q000096:biosynthesis; D014664:Vasodilation / Q000187:drug effects
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001685:Biological Factors; C067410:endothelium-dependent hyperpolarization factor; D009569:Nitric Oxide; D001920:Bradykinin